Utah Medical Products maintains a Hold rating due to ongoing revenue declines and concerns over capital allocation despite recent actions. UTMD's Q3 2026 saw a 12.1% revenue decline but a 5.9% net income increase, driven by lower litigation and amortization expenses. Management deployed cash via a $25M share repurchase at $75/share and acquired Orion Medical Supplies, aiming to offset core business weakness.
I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. In this second article in two parts, I highlight 17 Dividend Contenders and 2 special dividends this week. Snap-on (SNA) stands out with a 12.7% dividend hike, 17-year streak, 7.68 Quality Score, and top-tier dividend safety.
Utah Medical's Q3 earnings per share rise 7% year over year despite a 12.1% revenue decline, aided by lower operating expenses. Management expects a smaller revenue decline for full-year 2026.
SALT LAKE CITY, UT / ACCESS Newswire / October 22, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period results. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
SALT LAKE CITY, UT / ACCESS Newswire / October 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The Offer was initially scheduled to expire at 5:00 p.m.
SALT LAKE CITY, UT / ACCESS Newswire / September 25, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The conditions of the Offer are explained in detail in the SEC Form TO Offer to Purchase and Letter of Transmittal filed with the SEC at https://www.sec.gov/Archives/edgar/data/706698/000109690626001428/0001096906-26-001428-index.html The Offer is scheduled to expire at 5:00 p.m.
SALT LAKE CITY, UT / ACCESS Newswire / September 24, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The $75.00 per share price represents a 17% premium over the average daily closing price of the stock during the last twelve months, and a 21% premium over the average daily closing price of the stock during the last twenty-four months.
SALT LAKE CITY, UT / ACCESS Newswire / September 15, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces today that it intends to repurchase at a price of $75.00 per share up to 650,000 of its shares, if tendered and not withdrawn by stockholders on or before October 7, representing approximately 20% of its currently outstanding shares. The offering price is 17% higher than the average daily closing price of UTMD shares trading in the open market during the last twelve months, and 21% higher than the average daily closing price of UTMD shares trading during the last two years.
BlackRock Inc. acquired a new position in shares of Utah Medical Products, Inc. (NASDAQ: UTMD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 203,690 shares of the medical instruments supplier's stock, valued at approximately $14,051,000. BlackRock Inc. owned 6.41% of Utah